Efficacy and safety of lowering LDL cholesterol in older patients: A systematic review and meta-analysis of randomized controlled trials
The Lancet — Gencer B, Marston NA, Im KA, et al. | November 24, 2020
In older patients, the present study was conducted to summarize the benefit of LDL cholesterol-lowering therapies. Researchers conducted a systematic review and meta-analysis to search MEDLINE and Embase for articles published between March 1, 2015, and August 14, 2020, with no language restrictions. Via the 2018 American College of Cardiology and American Heart Association guidelines, researchers enrolled randomized controlled trials of cardiovascular outcomes of recommended LDL cholesterol-lowering drugs, with a median follow-up of at least 2 years and data on older patients (aged ≥ 75 years). The data revealed that the lipid-lowering was as effective in reducing cardiovascular events in patients aged 75 years and older as it was in patients younger than 75 years. As per the data, these outcomes should strengthen guideline recommendations for the use of lipid-lowering therapies, including non-statin treatment, in older individuals.
Read the full article on The Lancet